Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
UBS
Chubb
Cipla
Citi

Generated: August 18, 2019

DrugPatentWatch Database Preview

Details for Patent: RE43390

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE43390 protect, and when does it expire?

Patent RE43390 protects ALTABAX and is included in one NDA.

This patent has fifty-six patent family members in thirty-five countries.

Summary for Patent: RE43390
Title:Pleuromutilin derivatives as antimicrobials
Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Berry; Valerie Joan (Chester Springs, PA), Dabbs; Steven (Harlow, GB), Frydrych; Colin Henry (Sawbridgeworth, GB), Hunt; Eric (Great Dunmow, GB), Sanderson; Francis Dominic (Harlow, GB), Woodnutt; Gary (Chester Springs, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA) SmithKline Beecham Limited (Brentford, Middlesex, GB)
Application Number:13/102,156
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use; Dosage form;

Drugs Protected by US Patent RE43390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE43390

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9722817Oct 29, 1997
United Kingdom9813689Jun 25, 1998
PCT Information
PCT FiledOctober 27, 1998PCT Application Number:PCT/GB98/03211
PCT Publication Date:May 06, 1999PCT Publication Number: WO99/21855

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Queensland Health
Merck
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.